◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › RZLT

Rezolute, Inc. (RZLT) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Rezolute, Inc. (RZLT) operates in the Biotechnology industry and is headquartered in Redwood City, United States with about 68 employees. Its market capitalization is roughly $494 million. In the fiscal year ended 2025-06-30, RZLT reported $0M in revenue and ($74M) in net income.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Interactive charts & full statements →

RZLT Revenue & Earnings History — Annual Income Statement

Income statement2025-06-302024-06-302023-06-302022-06-30
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($80M)($70M)($56M)($42M)
Net Income($74M)($68M)($52M)($41M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RZLT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($17M)($24M)($20M)($26M)($20M)
Net Income($16M)($23M)($18M)($24M)($19M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RZLT Free Cash Flow History

RZLT Balance Sheet History

Balance sheet2025-06-302024-06-302023-06-302022-06-30
Total Assets$176M$133M$124M$152M
Total Liabilities$13M$12M$8M$3M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RZLT viewer.

Other Companies in Biotechnology

← RYZAll stocksRZLV →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.